The study of novel DNA vaccines against tuberculosis: Induction of pathogen-specific CTL in the mouse and monkey models of tuberculosis

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 3, 2013, Pages 515-525

  Okada, Masaji ^a   Kita, Yoko ^a   Nakajima, Toshihiro ^b   Hashimoto, Satomi ^a   Nakatani, Hitoshi ^a   Nishimatsu, Shiho ^a   Nishida, Yasuko ^a   Kanamaru, Noriko ^a   Kaneda, Yasuhumi ^c   Takamori, Yasushi ^d   McMurray, David ^e   Tan, Esterlina V ^f   Cang, Marjorie L ^f   Saunderson, Paul ^f   Dela Cruz, E C ^f  

^a NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^b GenomIdea Inc   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d TSURUMI UNIVERSITY   (Japan)

^e TEXAS A M COLLEGE OF MEDICINE   (United States)

^f Leonard Wood Memorial Institute   (Philippines)

Author keywords

CTL; Granulysin vaccine; HVJ Envelope; Ksp37; Mice; Monkeys; Tuberculosis; Vaccines against tuberculosis

Indexed keywords

BCG VACCINE; DNA VACCINE; GAMMA INTERFERON; GRANULYSIN; INTERLEUKIN 2; INTERLEUKIN 6; BACTERIAL PROTEIN; CHAPERONIN 60; GNLY PROTEIN, HUMAN; HEAT-SHOCK PROTEIN 65, MYCOBACTERIUM; INTERLEUKIN 12; KSP37 PROTEIN, HUMAN; PLASMA PROTEIN; T LYMPHOCYTE ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BCG VACCINATION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; HAPLORHINI; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TUBERCULOSIS; ANIMAL; BAGG ALBINO MOUSE; DBA MOUSE; DISEASE MODEL; FEMALE; GENETICS; IMMUNOLOGY; JAPAN; MACACA FASCICULARIS; MYCOBACTERIUM TUBERCULOSIS; SECRETION (PROCESS);

ANIMALS; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; BACTERIAL PROTEINS; BLOOD PROTEINS; CHAPERONIN 60; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-2; JAPAN; MACACA FASCICULARIS; MICE, INBRED BALB C; MICE, INBRED DBA; MYCOBACTERIUM TUBERCULOSIS; T-LYMPHOCYTES, CYTOTOXIC; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, DNA;

EID: 84874718112     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.23229     Document Type: Conference Paper

References (34)

1. Yoshida S, Tanaka T, Kita Y, Kuwayama S, Kanamaru N, Muraki Y, et al. DNAvaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation.vaccine 2006; 24:1191-204; PMID:16216394; http://dx.doi.org/10.1016/ j.vaccine.2005.08.103. (Pubitemid 43202265)
2. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Novel prophylacticvaccine using a prime-boost method and hemagglutinating virus of Japan-envelope against tuberculosis. Clin Dev Immunol 2011; 2011:549281; PMID:21437226; http://dx.doi.org/10.1155/2011/549281.
3. Boom WH. New TBvaccines: is there a requirement for CD8 T cells? J Clin Invest 2007; 117:2092-4; PMID:17671648; http://dx.doi.org/10.1172/JCI32933.
4. van Pinxteren LA, Cassidy JP, Smedegaard BH, Agger EM, Andersen P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 2000; 30:3689-98; PMID:11169412; http://dx.doi.org/10.1002/ 1521-4141(200012)30:12<3689::AIDIMMU3689> 3.0.CO;2-4.
5. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Evaluation of a novelvaccine (HVJ-liposome/HSP65 DNA+IL-12 DNA) against tuberculosis using the cynomolgus monkey model of TB.vaccine 2007; 25:2990-3; PMID:17280753; http://dx.doi.org/10.1016/j.vaccine. 2007.01.014. (Pubitemid 46509463)
6. Okada M, Kita Y. Tuberculosisvaccine development: The development of novel (preclinical) DNAvaccine. Hum Vaccin 2010; 6:297-308; PMID:20372079; http://dx.doi.org/10.4161/hv.6.4.10172.
7. Walsh GP, Tan EV, dela Cruz EC, Abalos RM, Villahermosa LG, Young LJ, et al. The Philippine cynomolgus monkey (Macaca fasicularis) provides a new nonhuman primate model of tuberculosis that resembles human disease. Nat Med 1996; 2:430-6; PMID:8597953; http://dx.doi.org/10.1038/nm0496-430. (Pubitemid 26191915)
8. Kita Y, Tanaka T, Yoshida S, Ohara N, Kaneda Y, Kuwayama S, et al. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model.vaccine 2005; 23:2132-5; PMID:15755583; http://dx.doi.org/10.1016/j. vaccine. 2005.01.057. (Pubitemid 40341439)
9. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Novel prophylactic and therapeuticvaccine against tuberculosis.vaccine 2009; 27:3267-70; PMID:19200841; http://dx.doi.org/10.1016/j.vaccine.2009.01.064.
10. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Novel therapeuticvaccine: granulysin and new DNAvaccine against Tuberculosis. Hum Vaccin 2011; 7(Suppl):60-7; PMID:21546794; http://dx.doi.org/10.4161/hv.7.0. 14563.
11. Kita Y, Okada M, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Development of therapeutic and prophylacticvaccine against Tuberculosis using monkey and transgenic mice models. Hum Vaccin 2011; 7(Suppl):108-14; PMID:21263229; http://dx.doi.org/10.4161/hv.7.0.14571.
12. Stegelmann F, Bastian M, Swoboda K, Bhat R, Kiessler V, Krensky AM, et al. Coordinate expression of CC chemokine ligand 5, granulysin, and perforin in CD8+ T cells provides a host defense mechanism against Mycobacterium tuberculosis. J Immunol 2005; 175:7474-83; PMID:16301655. (Pubitemid 41713445)
13. Woodworth JS, Behar SM. Mycobacterium tuberculosis-specific CD8+ T cells and their role in immunity. Crit Rev Immunol 2006; 26:317-52; PMID:17073557; http://dx.doi.org/10.1615/CritRevImmunol.v26.i4.30. (Pubitemid 44423550)
14. Lewinsohn DM, Zhu L, Madison VJ, Dillon DC, Fling SP, Reed SG, et al. Classically restricted human CD8+ T lymphocytes derived from Mycobacterium tuberculosis-infected cells: definition of antigenic specificity. J Immunol 2001; 166:439-46; PMID:11123322.
15. Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, Froelich CJ, et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 1998; 282:121-5; PMID:9756476; http://dx.doi.org/10.1126/science.282. 5386.121.
16. Castiello L, Stroncek DF, Finn MW, Wang E, Marincola FM, Clayberger C, et al. 15 kDa Granulysin versus GM-CSF for monocytes differentiation: analogies and differences at the transcriptome level. J Transl Med 2011; 9:41; PMID:21501511; http://dx.doi.org/10.1186/1479-5876-9-41.
17. Clayberger C, Finn MW, Wang T, Saini R, Wilson C, Barr VA, et al. 15 kDa granulysin causes differentiation of monocytes to dendritic cells but lacks cytotoxic activity. J Immunol 2012; 188:6119-26; PMID:22586033; http://dx.doi.org/10.4049/jimmunol. 1200570.
18. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004; 10:1240-4; PMID:15502839; http://dx.doi.org/10.1038/nm1128. (Pubitemid 39540442)
19. Fletcher HA, Pathan AA, Berthoud TK, Dunachie SJ, Whelan KT, Alder NC, et al. Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.vaccine 2008; 26:5269-75; PMID:18682270; http://dx.doi.org/ 10.1016/j.vaccine. 2008.07.040.
20. Kaufmann SH, Hussey G, Lambert PH. Newvaccines for tuberculosis. Lancet 2010; 375:2110-9; PMID:20488515; http://dx.doi.org/10.1016/S0140-6736(10)60393- 5.
21. Rahman S, Magalhaes I, Rahman J, Ahmed RK, Sizemore DR, Scanga CA, et al. Prime-boost vaccination with rBCG/rAd35 enhances CD8+ cytolytic T-cell responses in lesions from Mycobacterium tuberculosis-infected primates. Mol Med 2012; 18:647-58; PMID:22396020; http://dx.doi.org/10.2119/molmed. 2011.00222.
22. Ogawa K, Tanaka K, Ishii A, Nakamura Y, Kondo S, Sugamura K, et al. A novel serum protein that is selectively produced by cytotoxic lymphocytes. J Immunol 2001; 166:6404-12; PMID:11342666. (Pubitemid 32440775)
23. Elgaaen BV, Haug KB, Wang J, Olstad OK, Fortunati D, Onsrud M, et al. POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas. PLoS One 2010; 5:e13837; PMID:21079801; http://dx.doi.org/10.1371/journal.pone.0013837.
24. Saeki Y, Matsumoto N, Nakano Y, Mori M, Awai K, Kaneda Y. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum Gene Ther 1997; 8:2133-41; PMID:9414261; http://dx.doi.org/10.1089/hum.1997.8. 17-2133.
25. Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N, et al. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther 2002; 6:219-26; PMID:12161188; http://dx.doi.org/10. 1006/mthe.2002.0647. (Pubitemid 36336129)
26. Kaneda Y. New vector innovation for drug delivery: development of fusigenic non-viral particles. Curr Drug Targets 2003; 4:599-602; PMID:14577648; http://dx.doi.org/10.2174/1389450033490740. (Pubitemid 37236374)
27. Kaneda Y, Yamamoto S, Nakajima T. Development of HVJ envelope vector and its application to gene therapy. Adv Genet 2005; 53:307-32; PMID:16240999; http://dx.doi.org/10.1016/S0065-2660(05)53012-8. (Pubitemid 43580672)
28. Ito M, Yamamoto S, Nimura K, Hiraoka K, Tamai K, Kaneda Y. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J Gene Med 2005; 7:1044-52; PMID:15756713; http://dx.doi.org/10.1002/jgm.753. (Pubitemid 41195066)
29. Mima H, Yamamoto S, Ito M, Tomoshige R, Tabata Y, Tamai K, et al. Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector. Mol Cancer Ther 2006; 5:1021-8; PMID:16648574; http://dx.doi.org/10.1158/1535-7163.MCT-05-0352. (Pubitemid 43724603)
30. Okada M, Yoshimura N, Kaieda T, Yamamura Y, Kishimoto T. Establishment and characterization of human T hybrid cells secreting immunoregulatory molecules. Proc Natl Acad Sci U S A 1981; 78:7717-21; PMID:6801660; http://dx.doi.org/10.1073/pnas.78.12.7717. (Pubitemid 12186633)
31. Tanaka F, Abe M, Akiyoshi T, Nomura T, Sugimachi K, Kishimoto T, et al. The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector. Cancer Res 1997; 57:1335-43; PMID:9102222. (Pubitemid 27152560)
32. Okada M, Sakaguchi N, Yoshimura N, Hara H, Shimizu K, Yoshida N, et al. B cell growth factors and B cell differentiation factor from human T hybridomas. Two distinct kinds of B cell growth factor and their synergism in B cell proliferation. J Exp Med 1983; 157:583-90; PMID:6600487; http://dx.doi.org/10. 1084/jem.157.2.583. (Pubitemid 13145061)
33. Okada M, Klimpel GR, Kuppers RC, Henney CS. The differentiation of cytotoxic T cells in vitro. I. Amplifying factor(s) in the primary response is Lyt 1 + cell dependent. J Immunol 1979; 122:2527-33; PMID:156228. (Pubitemid 9197249)
34. Okada M, Sakaguchi N, Yoshimura N, Hara H, Shimizu K, Yoshida N, et al. B cell growth factors and B cell differentiation factor from human T hybridomas. Two distinct kinds of B cell growth factor and their synergism in B cell proliferation. J Exp Med 1983; 157:583-90; PMID:6600487; http://dx.doi.org/10. 1084/jem.157.2.583. (Pubitemid 13145061)